Mads Hald Andersen PhD

Mads Hald Andersen is vice-director at Center for Cancer Immune Therapy at Copenhagen University Hospital at Herlev as well as professor at Department of Immunology and Microbiology at Copenhagen University. In 2001 he gained his PhD from the Danish Cancer Society, Copenhagen, Denmark, and the Department of Dermatology, Würzburg University, Germany. The same year he co-founded the Tumor Immunology Group at the Danish Cancer Society. He obtained his DScTech in 2006, the same year as he co-founded the Center for Cancer Immune Therapy at Copenhagan University Hospital at Herlev. In 2015 he additionally achieved the DMSc degree from Copenhagen University. Professor Andersen has considerable pharmaceutical experience, and has founded several biotech companies including Survac, Rhovac and most recently IO Biotech Aps.

He has been honored with several awards during his career including The Lundbeck Foundation research prize (2012), the Danish Cancer Society Research Award (2006) and the Hallas-Møller Stipend from the Novo Nordisk foundation (2007). He has an extensive publication record, authoring over 150 publications in peer reviewed journals, more than 15 patents as well as several book chapters. His research has been focusing on the characterization of the natural immune responses towards malignant cells. He has identified a number of different T-cell antigens including survivin, the Bcl-2 family and RhoC. Recently, he described circulating T cells that specifically target normal, self-proteins, e.g., IDO, TDO, PD-L1 and Foxp3, expressed by regulatory immune cells and defined these as anti-Tregs.